These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 9032889

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine.
    Elvin SJ, Eyles JE, Howard KA, Ravichandran E, Somavarappu S, Alpar HO, Williamson ED.
    Vaccine; 2006 May 15; 24(20):4433-9. PubMed ID: 16546306
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Cell-mediated immune response and Th/Th cytokine profile of B-T constructs of F1 and V antigen of Yersinia pestis.
    Gupta G, Khan AA, Rao DN.
    Scand J Immunol; 2010 Mar 15; 71(3):186-98. PubMed ID: 20415784
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
    Dinc G, Pennington JM, Yolcu ES, Lawrenz MB, Shirwan H.
    Vaccine; 2014 Sep 03; 32(39):5035-40. PubMed ID: 25045812
    [Abstract] [Full Text] [Related]

  • 9. Enhanced humoral and mucosal immune responses after intranasal immunization with chimeric multiple antigen peptide of LcrV antigen epitopes of Yersinia pestis coupled to palmitate in mice.
    Uppada SB, Bhat AA, Sah A, Donthamshetty RN.
    Vaccine; 2011 Nov 21; 29(50):9352-60. PubMed ID: 22001881
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles.
    Sabhnani L, Manocha M, Sridevi K, Shashikiran D, Rayanade R, Rao DN.
    FEMS Immunol Med Microbiol; 2003 Oct 15; 38(3):215-29. PubMed ID: 14522457
    [Abstract] [Full Text] [Related]

  • 12. Cellular and humoral responses to microencapsulated Yersinia pestis subunit vaccines following oral delivery.
    Sharp GJ, Eyles JE, Williamson ED, Brown MR, Alpar HO.
    Biochem Soc Trans; 1997 May 15; 25(2):338S. PubMed ID: 9191383
    [No Abstract] [Full Text] [Related]

  • 13. A new improved sub-unit vaccine for plague: the basis of protection.
    Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A.
    FEMS Immunol Med Microbiol; 1995 Dec 15; 12(3-4):223-30. PubMed ID: 8745007
    [Abstract] [Full Text] [Related]

  • 14. Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines.
    Eyles JE, Spiers ID, Williamson ED, Alpar HO.
    Vaccine; 1998 Dec 15; 16(20):2000-9. PubMed ID: 9796057
    [Abstract] [Full Text] [Related]

  • 15. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy.
    Eyles JE, Williamson ED, Spiers ID, Alpar HO.
    Vaccine; 2000 Aug 01; 18(28):3266-71. PubMed ID: 10869771
    [Abstract] [Full Text] [Related]

  • 16. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE, Derbise A, Guillas C, Gerke C, Cauchemez S, Carniel E, Pizarro-Cerdá J.
    Vaccine; 2019 Jan 03; 37(1):123-129. PubMed ID: 30467064
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.